Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

Glaxosmithkline (GSK) Share News

LONDON BROKER RATINGS: Goldman likes Haleon but says sell Schroders

20th Jul 2022 09:41

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday: Read More

LONDON MARKET CLOSE: Stocks rise on Nord Stream 1 restart report

19th Jul 2022 17:06

(Alliance News) - Stocks in London ended higher on Tuesday amid hopes of a restart of natural gas supplies after months of brinkmanship by Russia over the flow to Germany and the rest of Europe. Read More

London handed listing boost as Haleon begins life as public company

18th Jul 2022 18:22

(Alliance News) - Haleon PLC, the consumer healthcare product arm of GSK, started trading on Monday, becoming effectively by far the biggest new listing in London in 2022, a poor year so far for initial public offerings in a post-Brexit landscape. Read More

LONDON MARKET CLOSE: Stocks rise as historic US Fed hike fears ease

18th Jul 2022 17:09

(Alliance News) - Stocks in London ended higher on Monday as investors reversed bets over a 100 basis points interest rate increase from the US Federal Reserve. Read More

LONDON MARKET MIDDAY: Dollar feels heat as Fed rate expectations cool

18th Jul 2022 12:13

(Alliance News) - Stocks in Europe were solidly higher midday Monday, as easing US rate hike expectations boosted risk appetite, taking some steam out of a rampant dollar. Read More

TOP NEWS SUMMARY: GSK spinoff Haleon starts life as public company

18th Jul 2022 11:19

(Alliance News) - The following is a summary of top news stories Monday. Read More

UK motor insurers struggling to get up to speed with claims inflation

18th Jul 2022 10:04

(Alliance News) - Motor insurance providers in the UK are being hit by accelerating claims inflation, Jefferies warned on Monday, and margins are suffering as a result. Read More

TOP NEWS: GSK completes demerger of healthcare product business

18th Jul 2022 08:32

(Alliance News) - GSK PLC on Monday confirmed it has completed the demerger of consumer healthcare business as Haleon PLC. Read More

LONDON MARKET PRE-OPEN: Euromoney takeover; Deliveroo cuts outlook

18th Jul 2022 07:50

(Alliance News) - Stock prices in London are seen opening higher on Monday, as Europe looks ahead to a key week on the political, monetary policy and energy market fronts. Read More

GSK consumer arm Haleon set to begin trading in London on Monday

15th Jul 2022 12:01

(Alliance News) - Haleon PLC, the consumer healthcare product arm of GSK PLC, will start trading on Monday, becoming effectively by far the biggest new listing in London in 2022, a poor year so far for initial public offerings. Read More

LONDON BROKER RATINGS: JPMorgan downgrades Admiral and Direct Line

15th Jul 2022 09:49

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday: Read More

IN BRIEF: GSK shareholders vote in favour of Haleon demerger

6th Jul 2022 19:20

GSK PLC - London-based pharmaceutical company - At general meeting, shareholders vote near unanimously in favour of proposed demerger of Haleon PLC from GSK, with the former's shares expected to list on the London Main Market at the open on July 18. Read More

IN BRIEF: Sareum notes updated payment terms after GSK buy of SRA737

4th Jul 2022 11:23

Sareum Holdings PLC - Cambridge, England-based drug developer for cancer and autoimmune diseases - Notes that GSK PLC has completed its acquisition of Sierra Oncology Inc, the licence holder of SRA737, for USD1.9 billion. SRA737 was discovered and initially developed by scientists at the Institute of Cancer Research in collaboration with Sareum. Read More

IN BRIEF: GSK completes acquisition of Sierra Oncology

1st Jul 2022 15:37

GSK PLC - London-based pharmaceutical company - Completes acquisition of Sierra Oncology Inc, for USD55 per share in cash, representing a total value of USD1.9 billion. Notes acquisition includes momelotinib, a late-stage potential treatment for myelofibrosis patients with anaemia. Last month, Sierra presented data for the treatment from phase III Momentum trial, which met all its key primary and secondary endpoints. The drug showed a statistically meaningful benefit on symptoms, splenic response, and anaemia. Read More

FTSE 100 Latest

Value8,287.42

Change11.76